BioSpace News Archive

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2022.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the markets close.

Taro Pharmaceutical Industries Ltd. announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission, is available within the Investor Relations section of Taro’s website.

Senseonics Holdings, Inc. (NYSE American: SENS) today announced that it plans to release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.

Scholar Rock announced that Dr. Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital, has been appointed to Scholar Rock’s Board of Directors as an independent director.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2022 before the market opens on August 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

AACC 2022 Open Lab Solutions, Inc., is announcing the formation of a new division, AMCAR Scientific, that will focus on an expanding product line of plastic consumables used in the medical industry.

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-based financial markets.

Brii Biosciences Limited today announced new live virus data confirming that the amubarvimab/romlusevimab combination, a long-acting COVID-19 monoclonal antibody (mAb) therapy, retains neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.